TESARO Announces Six Abstracts to be Presented at the 2015 Multinational Association of Supportive Care in Cancer Annual Meeting

WALTHAM, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. TSRO, an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2015 Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Annual Meeting, June 25 to 27, 2015, in Copenhagen.

Presentation Details:

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly- or moderately emetogenic chemotherapy (HEC; MEC)
Abstract: 11-03-O, Oral Presentation, Friday, June 26, 2015 from 5:45 PM to 7:15 PM

Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)
Abstract: 11-38-P, Poster Presentation, Friday, June 26, 2015

Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline/cyclophosphamide (A/C) moderately emetogenic therapy (MEC)
Abstract: 11-39-P, Poster Presentation, Friday, June 26, 2015

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) using anthracycline-cyclophosphamide (AC)-based chemotherapy
Abstract: 11-11-P, Poster Presentation, Friday, June 26, 2015

Pharmacokinetics of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy volunteers 
Abstract: 11-20-P, Poster Presentation, Friday, June 26, 2015

Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of rolapitant, a novel NK-1 receptor antagonist 
Abstract: 11-07-P, Poster Presentation, Friday, June 26, 2015

Rolapitant is an investigational product candidate that has not been approved by any regulatory agency.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

TESARO, Inc. Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!